First Affirmative Financial Network Makes New $226,000 Investment in Takeda Pharmaceutical Company Limited (NYSE:TAK)

First Affirmative Financial Network purchased a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) in the 3rd quarter, Holdings Channel.com reports. The fund purchased 15,866 shares of the company’s stock, valued at approximately $226,000.

A number of other hedge funds also recently modified their holdings of TAK. Bleakley Financial Group LLC increased its position in shares of Takeda Pharmaceutical by 19.1% during the first quarter. Bleakley Financial Group LLC now owns 288,535 shares of the company’s stock worth $4,008,000 after buying an additional 46,182 shares during the period. Envestnet Portfolio Solutions Inc. raised its position in shares of Takeda Pharmaceutical by 7.4% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 25,763 shares of the company’s stock worth $358,000 after acquiring an additional 1,778 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Takeda Pharmaceutical by 0.7% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 130,904 shares of the company’s stock valued at $1,818,000 after purchasing an additional 857 shares during the period. Van ECK Associates Corp boosted its position in shares of Takeda Pharmaceutical by 21.1% during the 2nd quarter. Van ECK Associates Corp now owns 2,040,829 shares of the company’s stock valued at $26,408,000 after purchasing an additional 356,069 shares in the last quarter. Finally, Blair William & Co. IL grew its stake in Takeda Pharmaceutical by 6.5% during the first quarter. Blair William & Co. IL now owns 12,649 shares of the company’s stock worth $176,000 after purchasing an additional 777 shares during the period. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Shares of TAK opened at $14.30 on Friday. The firm has a market cap of $45.50 billion, a PE ratio of 26.98, a price-to-earnings-growth ratio of 0.27 and a beta of 0.54. Takeda Pharmaceutical Company Limited has a 52-week low of $12.57 and a 52-week high of $15.39. The business’s 50 day moving average price is $14.56 and its two-hundred day moving average price is $13.75. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 1.26.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. The company had revenue of $7.75 billion for the quarter. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. On average, equities analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.58 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.